Home・Akciju saraksts・Compugen Ltd

Compugen Ltd

Slēgts

2.6 -5.11

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.58

Max

2.62

Galvenie mērījumi
By Trading Economics
Ienākumi	663K -7M
Pārdošana	426K 2.6M
P/E Sektora vidējais	6.816 57.366
EPS	-0.07
Peļņas marža	-269.254
Darbinieki	75
EBITDA	665K -7M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+92.31% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 9. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	20M 245M
Iepriekšējā atvēršanas cena	7.71
Iepriekšējā slēgšanas cena	2.6

Compugen Ltd Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. aug. 23:51 UTC

"Bitcoin and Ethereum Rise Amid Market Uncertainty; Barclays Warns of Commodity Shock, Fed Signals Possible Rate Hikes, and Canada's GDP Growth Falls Short of Expectations."

2026. g. 29. aug. 23:51 UTC

Bitcoin and Ethereum rise amid economic uncertainties, while Barclays warns of a commodity shock and Fed Chair hints at potential interest rate hikes.

2026. g. 29. aug. 23:51 UTC

Cryptocurrency gains amid economic uncertainty; Barclays warns of commodity shock from El Niño, while Fed signals potential rate hikes and Canada faces trade tensions.

2026. g. 29. aug. 23:51 UTC

Cryptocurrency gains amid economic uncertainty, while Barclays warns of commodity shocks and Fed signals potential rate hikes, impacting U.S. stock markets and Canadian trade tensions.

2026. g. 29. aug. 23:41 UTC

U.S. Import Data Release on September 3, 2026 Expected to Reflect Impact of Tariff Changes Amid Escalating Trade Tensions with Canada.

2026. g. 29. aug. 23:41 UTC

U.S. Trade Deficit Expected to Widen to $86.4 Billion Amid Ongoing Tariff Tensions with Canada

2026. g. 29. aug. 23:41 UTC

Mexican Business Confidence Remains Low Ahead of September Survey, Anticipating Continued Economic Challenges

2026. g. 29. aug. 23:41 UTC

U.S. July 2026 export data release on September 3 expected to reflect ongoing trade challenges amid U.S.-Canada tariff tensions, raising market volatility concerns.

2026. g. 29. aug. 23:41 UTC

Canada's Balance of Trade Expected to Show C$3.2 Billion Surplus Amid Rising U.S.-Canada Tariff Tensions

2026. g. 29. aug. 23:31 UTC

Brazil's Q2 2026 GDP Growth Rate Release on September 1st Sparks Cautious Optimism Amid Economic Challenges and Global Trade Tensions.

2026. g. 29. aug. 23:31 UTC

South Africa's Balance of Trade report on August 31 expected to reveal if trade surplus continues amid concerns over El Niño impacts and global commodity markets.

2026. g. 29. aug. 23:11 UTC

ADP Employment Change report on September 2 forecasts a modest increase of 47,000 jobs amid cautious labor market sentiment and potential downward revisions in nonfarm payrolls.

2026. g. 29. aug. 23:11 UTC

Mexican Consumer Confidence Index Set for Release on September 3, Amid Global Economic Uncertainty and Mixed Sentiments.

2026. g. 29. aug. 23:01 UTC

Macro News

DAX 30 Index declines in after-market hours, pressured by hawkish Fed remarks and geopolitical tensions. The index remains near its one-month low.

2026. g. 29. aug. 22:52 UTC

Japan's Household Spending Data Release Sparks Caution Amid Rising Inflation Concerns and Weak Investor Confidence

2026. g. 29. aug. 22:52 UTC

Japan's Household Spending Expected to Decline by -1.6% YoY Amid Inflation Concerns and Weak Consumer Sentiment

2026. g. 29. aug. 22:52 UTC

Brazil's Q2 GDP Growth Rate Release on September 1, 2026, Sparks Cautious Market Anticipation Amid Global Economic Uncertainties.

2026. g. 29. aug. 22:51 UTC

Correlated Moves

Barclays reports a potential commodity shock from adverse weather and underinvestment. In after-market trading, Silver Ounce vs Euro is roughly flat near its one-month range.

2026. g. 29. aug. 22:41 UTC

Upcoming MBA Mortgage Rate Release Sparks Cautious Investor Sentiment Amid Inflation and Fed Hike Expectations

2026. g. 29. aug. 22:11 UTC

Germany's Inflation Rate Expected to Rise to 2.9% in August Amid Fed Concerns Over Elevated Prices

2026. g. 29. aug. 22:11 UTC

Germany's Inflation Rate Release on August 31 Sparks Investor Caution Amid Persistent Price Pressures and Potential Monetary Policy Tightening.

2026. g. 29. aug. 22:11 UTC

Japan's Q2 2026 Capital Spending YoY data set for release, with a modest growth forecast of 0.2% amid cautious investor sentiment and rising inflation concerns.

2026. g. 29. aug. 21:51 UTC

Japan's Industrial Production Expected to Contract 0.006% in July Amid Mixed Economic Sentiment and Rising Inflation Concerns

2026. g. 29. aug. 21:51 UTC

Japan's Retail Sales YoY data for July 2026 expected to rise by 0.3% amid mixed economic signals and wavering investor confidence ahead of the release on August 30, 2026.

2026. g. 29. aug. 21:41 UTC

South Africa's Business Confidence Index set for release amid cautious market sentiment following significant declines and ongoing geopolitical uncertainties.

2026. g. 29. aug. 21:41 UTC

Australia's Ai Group Industry Index set for release on September 1, 2026, amid cautious expectations of continued industrial contraction due to high costs and subdued demand.

2026. g. 29. aug. 21:41 UTC

South Korea's Upcoming Inflation Rate Release on September 1, 2026, Expected to Impact Economic Outlook Amid Mixed Market Sentiment and Global Price Pressures.

2026. g. 29. aug. 21:31 UTC

API Crude Oil Stock Change Data Release on September 1, 2026, Expected to Impact U.S. Market Amid Rising Inventories and Geopolitical Tensions

2026. g. 29. aug. 20:41 UTC

India's Q2 2026 GDP Growth Rate Forecast at 7.1% Amid Cautious Optimism and Global Economic Pressures

2026. g. 29. aug. 20:31 UTC

Euro Area Retail Sales Expected to Rise 0.3% in July Amid Mixed Economic Signals and Caution from Spain's Decline

Salīdzinājums

Cenas izmaiņa

Compugen Ltd Prognoze

Cenas mērķis

By TipRanks

92.31% augšup

Prognoze 12 mēnešiem

Vidējais 5 USD 92.31%

Augstākais 6 USD

Zemākais 4 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Compugen Ltd — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Compugen Ltd — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.